Vir Biotechnology Inc (VIR) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Vir Biotechnology Inc (VIR) following the 2026 Q2 hedge fund 13F filings?

As of today, VIR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), VIR gained -9.3% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Vir Biotechnology Inc (VIR)

249 + Investors. Track Smart Money conviction in VIR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — VIR

Based on 250 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added VIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

250 hedge funds hold VIR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q

+18 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟢

More buyers than sellers — 71% buying

185 buying77 selling

Last quarter: 185 funds were net buyers (66 opened a brand new position + 119 added to an existing one). Only 77 were sellers (45 trimmed + 32 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+31 vs last Q)

new funds entering per quarter

Funds opening a new VIR position: 22 → 27 → 35 → 66. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

54% of holders stayed for 2+ years

■ 54% conviction (2yr+) ■ 24% medium ■ 22% new

136 out of 250 hedge funds have held VIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Value +77% but shares only +20% — price-driven

Value

+77%

+20%

Last quarter: the total dollar value of institutional holdings rose +77%, but actual share count only changed +20%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

51 → 22 → 27 → 35 → 66 new funds/Q

New funds entering each quarter: 22 → 27 → 35 → 66. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 64% veterans vs 25% newcomers

■ 64% veterans ■ 11% 1-2yr ■ 25% new

Entry-cohort mix of 259 holders: 165 (64%) are 2+ year veterans, 29 entered 1–2 years ago, and 65 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds

46 of 247 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.7

out of 10

Low Exit Risk

Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	249	215	15.81%
13F Shares	139M	116M	20.27%
Total Value	$1.24B	$697M	77.28%
New Positions	65	35	+30
Increased Positions	117	64	+53
Closed Positions	31	30	+1
Reduced Positions	43	77	-34
Total Calls	7	6	16.67%
Total Puts	5	2	150.0%
PUT/CALL Ratio	0.71	0.33	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

249

215

15.81%

13F Shares

139M

116M

20.27%

Total Value

$1.24B

$697M

77.28%

New Positions

+30

Increased Positions

117

+53

Closed Positions

Reduced Positions

-34

Total Calls

16.67%

Total Puts

150.0%

PUT/CALL Ratio

0.71

0.33

Neutral

Institutional Holders (2026 Q2)

249 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VIR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 VIR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	GSK plc	14.47%	8,550,954	$87.1M
2	ARCH Venture Management, LLC	11.76%	12,694,163	$129.4M
3	GordonMD Global Investments LP	6.67%	1,353,552	$13.8M
4	Superstring Capital Management LP	5.49%	853,685	$8.7M
5	Alta Partners Management Company, L.P.	4.08%	509,917	$5.2M
6	Sio Capital Management, LLC	1.81%	1,075,274	$11.0M
7	Sb Investment Advisers (uk) Ltd	1.46%	10,948,093	$111.6M
8	Boxer Capital Management, LLC	1.43%	1,866,000	$19.0M
9	Jones Hill Capital LP	1.43%	659,213	$6.7M
10	ADAR1 Capital Management, LLC	1.15%	2,456,677	$25.0M
11	Saturn V Capital Management LP	1.13%	770,643	$7.9M
12	Birchview Capital, LP	1.05%	220,000	$2.2M
13	Avidity Partners Management LP	0.85%	519,300	$5.3M
14	Parkman Healthcare Partners LLC	0.50%	475,279	$4.8M
15	Act Capital Management, LLC	0.43%	64,300	$655K
16	Soleus Capital Management, L.P.	0.35%	1,000,000	$10.2M
17	Savvy Advisors, Inc.	0.23%	1,040,665	$10.6M
18	Algert Global LLC	0.10%	804,977	$8.2M
19	Virtus Investment Advisers, LLC	0.09%	38,002	$387K
20	Eversept Partners, LP	0.08%	156,636	$1.6M
21	Headlands Technologies LLC	0.07%	64,299	$655K
22	Point72 Asset Management, L.P.	0.06%	5,666,821	$57.7M
23	Nano Cap New Millennium Growth Fund L P	0.06%	7,500	$76K
24	Clearstead Advisors, LLC	0.06%	608,234	$6.2M
25	Susquehanna Portfolio Strategies, LLC	0.06%	345,541	$3.5M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Vir Biotechnology Inc (VIR)

What does the Smart Money Trend signal show for VIR?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added VIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VIR?

More buyers than sellers — 71% buying: Last quarter: 185 funds were net buyers (66 opened a brand new position + 119 added to an existing one). Only 77 were sellers (45 trimmed + 32 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for VIR holders?

Strong quality — 38% AUM from major funds: 46 of 247 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held VIR?

54% of holders stayed for 2+ years: 136 out of 250 hedge funds have held VIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Vir Biotechnology Inc (VIR) following the 2026 Q2 hedge fund 13F filings?

As of today, VIR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), VIR has gained -9.3% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Vir Biotechnology Inc (VIR)

Smart Money Signals — VIR

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Steady growth — +8% more funds vs a year ago

More buyers than sellers — 71% buying

More new buyers each quarter (+31 vs last Q)

54% of holders stayed for 2+ years

Value +77% but shares only +20% — price-driven

Acceleration phase — new buyers rushing in

Veteran-anchored — 64% veterans vs 25% newcomers

Strong quality — 38% AUM from major funds

Institutional Sentiment Summary — VIR

Hedge Fund Ownership: VIR

Market Analysis: VIR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: VIR

Is It Too Late to Buy Vir Biotechnology Inc (VIR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: VIR

Statistics: VIR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Vir Biotechnology Inc (VIR)

Welcome to 13Foresight!